All In Biotech

Drug Trial Radar · NCT04345900

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

A Phase 2, Multicenter, Randomized Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1)

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Apr 5, 2017

Primary completion

Mar 20, 2018

Study completion Apr 20, 2018

Sponsor

Sponsor type
Industry
First posted
Apr 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count was to be assessed at baseline (prior to Cycle 1 docetaxel dose) and during Cycle 1 on Days 1, 2, 6, 7, 8, 9, 10, and 15 (pre-dose on dosing days; times equivalent to pre dose on other days).

Conditions

  • Chemotherapy-induced Neutropenia

Interventions

  • PlinabulinDrug

    a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

  • PegfilgrastimDrug

    PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DSNTime frame: At the end of Cycle 1 (each cycle is 21 days)

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • Emad Ibrahim, MD, Inc.

    Redlands, California

  • Mid Florida Hematology & Oncology Center

    Orange City, Florida

  • Cancer Center of Middle Georgia

    Dublin, Georgia

  • Hematology/Oncology of the North Shore

    Skokie, Illinois

  • Harbin Medical University Cancer Hospital

    Harbin, Harbin, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Medical University 'REAVIZ'

    Samara, Russia

  • SBI of Healthcare "Oncology Dispensary #2" Ministry of Healthcare of Krasnodar Region

    Sochi, Russia

  • Volgograd Regional Clinical Oncology Dispensary

    Volgograd, Russia

  • Municipal Institution Dnipropetrovsk City Multi-functional Hospital

    Dnipro, Ukraine

  • Prykarpatian Clinical Oncological Center

    Ivano-Frankivsk, Ukraine

  • Kherson regional oncological dispensary Communal Institution of Kherson Regional council

    Kherson, Ukraine

  • Regional Municipal Institution "Kryvyy Rig Oncology Dispensary"

    Krivói Rog, Ukraine

  • Kirovograd Regional Oncological Center

    Kropyvnytskyi, Ukraine

  • Kyiv City Clinical Oncology Center

    Kyiv, Ukraine

  • Lviv State Oncological Regional Treatment and Preventive Center

    Lviv, Ukraine

  • Municipal Institution "Sumy Regional Clinical Oncology Dispensary"

    Sumy, Ukraine

  • Zakarpattia Regional Clinical Oncology Center

    Uzhhorod, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.